CORRIGENDUM: ACMG recommendations for reporting of incidental findings in clinical exome and genome sequencing

Genet Med (2013) 15, 565–574 doi:10.1038/gim.2013.73 In the published version of this paper, on page 567, on the 16th line in the last paragraph of the left column, the abbreviation of Expected Pathogenic is incorrect. The correct sentence should read, “For the purposes of these recommendations, variants fitting these descriptions were labeled as Known Pathogenic (KP) and Expected Pathogenic (EP), respectively.

[1]  Dan M. Roden,et al.  Implementing genomic medicine in the clinic: the future is here , 2013, Genetics in Medicine.

[2]  Robert C. Green,et al.  Managing incidental findings and research results in genomic research involving biobanks and archived data sets , 2012, Genetics in Medicine.

[3]  Peter Saffrey,et al.  Rapid Whole-Genome Sequencing for Genetic Disease Diagnosis in Neonatal Intensive Care Units , 2012, Science Translational Medicine.

[4]  Muin J Khoury,et al.  Deploying whole genome sequencing in clinical practice and public health: Meeting the challenge one bin at a time , 2011, Genetics in Medicine.

[5]  I. Kohane,et al.  Taxonomizing, sizing, and overcoming the incidentalome , 2012, Genetics in Medicine.

[6]  A. Bassett,et al.  Incomplete Knowledge of the Clinical Context as a Barrier to Interpreting Incidental Genetic Research Findings , 2013, The American journal of bioethics : AJOB.

[7]  G. Friedman,et al.  Screening in chronic disease , 2004, Cancer Causes & Control.

[8]  A. Cambon-Thomsen,et al.  Genomic Incidental Findings: Reducing the Burden to Be Fair , 2013, The American journal of bioethics : AJOB.

[9]  H. Jacob,et al.  A timely arrival for genomic medicine , 2011, Genetics in Medicine.

[10]  Marylyn D. Ritchie,et al.  Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network , 2012, Genetics in Medicine.

[11]  Robert C. Green,et al.  Exploring concordance and discordance for return of incidental findings from clinical sequencing , 2012, Genetics in Medicine.

[12]  Janet K. Williams,et al.  Informed Consent and Genomic Incidental Findings: IRB Chair Perspectives , 2011, Journal of empirical research on human research ethics : JERHRE.

[13]  James P Evans,et al.  An informatics approach to analyzing the incidentalome , 2012, Genetics in Medicine.

[14]  R. Pyeritz,et al.  The coming explosion in genetic testing--is there a duty to recontact? , 2011, The New England journal of medicine.

[15]  L. Parker.  The Future of Incidental Findings: Should They Be Viewed as Benefits? , 2008, The Journal of law, medicine & ethics : a journal of the American Society of Law, Medicine & Ethics.

[16]  Laura M. Beskow,et al.  Offering Individual Genetic Research Results: Context Matters , 2010, Science Translational Medicine.

[17]  Larry N. Singh,et al.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. , 2012, American journal of human genetics.

[18]  E. Zerbin-Rüdin.  [Genetics in medicine]. , 1969, Wiener medizinische Wochenschrift.

[19]  Muin J. Khoury,et al.  The evidence dilemma in genomic medicine. , 2008, Health affairs.

[20]  R. Steiner,et al.  “I'm fine; I'm just waiting for my disease” , 2011, Neurology.

[21]  W. Grody,et al.  ACMG recommendations for standards for interpretation and reporting of sequence variations: Revisions 2007 , 2008, Genetics in Medicine.

[22]  J. Braithwaite,et al.  The outcomes for patients with incidental lesions: serendipitous or iatrogenic? , 1998, AJR. American journal of roentgenology.

[23]  Leslie G. Biesecker,et al.  Opportunities and challenges for the integration of massively parallel genomic sequencing into clinical practice: lessons from the ClinSeq project , 2012, Genetics in Medicine.

[24]  J. Friedman,et al.  Genetics professionals' perspectives on reporting incidental findings from clinical genome‐wide sequencing , 2013, American journal of medical genetics. Part A.

[25]  R. Sharp,et al.  Ethical and Policy Issues in Genetic Testing and Screening of Children , 2016, Pediatric Clinical Practice Guidelines & Policies.

[26]  Misha Angrist,et al.  You never call, you never write: why return of 'omic' results to research participants is both a good idea and a moral imperative. , 2011, Personalized medicine.

[27]  B. Knoppers,et al.  Population studies: return of research results and incidental findings Policy Statement , 2012, European Journal of Human Genetics.

[28]  M. Khoury,et al.  Population screening in the age of genomic medicine. , 2003, The New England journal of medicine.

[29]  Emily Farrow,et al.  Clinical genome sequencing in an unbiased pediatric cohort , 2018, Genetics in Medicine.

[30]  A. StAteMent.  Points to consider in the clinical application of genomic sequencing , 2012, Genetics in Medicine.

[31]  P. Farrell,et al.  Estimating the annual number of false negative cystic fibrosis newborn screening tests , 2012, Pediatric pulmonology.

[32]  L. Ross,et al.  From genetics to genomics: ethics, policy, and parental decision-making. , 2009, Journal of pediatric psychology.

[33]  B. Ness,et al.  Genomic Research and Incidental Findings , 2008 .

[34]  H. Saal,et al.  Ethical and Policy Issues in Genetic Testing and Screening of Children , 2013, Pediatrics.

[35]  Public health genomics: The end of the beginning , 2011, Genetics in Medicine.